CERo Therapeutics Holdings, Inc.
CERO
$5.40
-$0.10-1.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 21.74% | -21.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.35% | 143.70% | |||
| Operating Income | -6.35% | -143.70% | |||
| Income Before Tax | -6.10% | -859.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.10% | -859.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.10% | -859.92% | |||
| EBIT | -6.35% | -143.70% | |||
| EBITDA | -6.58% | -151.64% | |||
| EPS Basic | -84.66% | 6.41% | |||
| Normalized Basic EPS | 64.52% | 30.60% | |||
| EPS Diluted | -84.66% | 6.41% | |||
| Normalized Diluted EPS | 64.52% | 30.60% | |||
| Average Basic Shares Outstanding | -86.44% | 175.81% | |||
| Average Diluted Shares Outstanding | -86.44% | 175.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||